Alvotech (ALVO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ALVO
Alvotech
$3.14
+0.32%
HEALTHCARE · Cap: $1.10B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 778583% more annual revenue ($4.46T vs $573.35M). ALVO leads profitability with a 12.1% profit margin vs 2.5%. ALVO trades at a lower P/E of 15.3x. TAK earns a higher WallStSmart Score of 60/100 (C).
ALVO
Avoid31
out of 100
Grade: F
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-210.9%
Fair Value
$1.56
Current Price
$3.14
$1.58 premium
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Earnings declined 58.4%
Negative free cash flow — burning cash
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALVO
The strongest argument for ALVO centers on Debt/Equity, P/E Ratio. Revenue growth of 10.6% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bear Case : ALVO
The primary concerns for ALVO are Market Cap, Return on Equity, EPS Growth.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
ALVO carries more volatility with a beta of 0.18 — expect wider price swings.
ALVO is growing revenue faster at 10.6% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (60/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alvotech
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?